LGND

Ligand Pharmaceuticals Inc

284.70

Sep 17 • 3:59 PM ET +9.50 (3.45%)

284.70

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Sep 17, 3:02 PMFalling oil and Treasury yields lift Ligand 3% alongside broad biotech rebound

Peers: BMRN IONS AXSM MDGL RYTM VKTX ALNY INCY KROS NBIX

| Held by: IJR VTI IWM VB VBR VXF XSMO IJT IWO SPSM

Scroll to Statements

Index	RUT
Market Cap	5.68B
Enterprise Value	5.45B
Income	197.22M
Sales	290.54M
Book/sh	48.57
Cash/sh	68.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jul 02, 2010
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	47
IPO	Nov 18, 1992

P/E	30.44
Forward P/E	23.50
PEG	1.10
P/S	19.53
P/B	5.86
P/C	4.18
P/FCF	43.16
EV/EBITDA	40.55
EV/Sales	18.76
Quick Ratio	30.96
Current Ratio	31.18
Debt/Eq	1.17
LT Debt/Eq	1.17
Option/Short	Yes / Yes

EPS (ttm)	9.35
EPS next Y	12.11
EPS next Q	2.30
EPS this Y	14.58%
EPS next Y	30.04%
EPS next 5Y	21.39%
EPS past 3/5Y	- -
Sales past 3/5Y	10.96% 7.54%
EPS Y/Y TTM	350.86%
Sales Y/Y TTM	54.89%
EPS Q/Q	813.40%
Sales Q/Q	33.73%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	17.92% 3.90%

Insider Own	2.45%
Insider Trans	-16.18%
Inst Own	114.60%
Inst Trans	9.65%
ROA	12.58%
ROE	21.96%
ROIC	9.40%
Gross Margin	84.28%
Oper. Margin	34.45%
Profit Margin	67.88%
SMA20	0.12%
SMA50	-2.66%
SMA200	20.85%
Trades

Shs Outstand	19.92M
Shs Float	19.45M
Short Float	12.76%
Short Ratio	6.95
Short Interest	2.48M
52W High	326.63 -12.84%
52W Low	163.45 74.18%
Volatility	3.41% 3.07%
ATR (14)	9.17
RSI (14)	48.74
Beta	1.19
Rel Volume	0.70
Avg Volume	356.92K
Volume	248,808

Perf Week	-1.57%
Perf Month	-1.00%
Perf Quarter	8.19%
Perf Half Y	35.88%
Perf YTD	50.58%
Perf Year	72.12%
Perf 3Y	359.34%
Perf 5Y	204.85%
Perf 10Y	281.86%
Recom	1.00
Target Price	352.40
Prev Close	275.20
Price	284.70
Change %	3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-26	Initiated	Leerink Partners	Outperform
Jul-21-26	Resumed	Citigroup	Buy	$387
Mar-11-26	Initiated	BofA Securities	Buy	$244
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300

Show Previous Ratings

Aug-26-26 07:00AM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-06-26 07:18PM	Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ... (GuruFocus.com)
06:40PM	Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary (Moby)
07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press)
07:00AM	Ligand Reports Second Quarter 2026 Financial Results (GlobeNewswire)
02:15PM	Loading…
Jul-27-26 02:15PM	This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026 (Investor's Business Daily)
Jul-23-26 07:00AM	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-21-26 09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jul-14-26 09:00AM	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets (GlobeNewswire)
Jul-13-26 12:53PM	Agenus shares surge as company secures up to $340M to advance colon cancer trial (Proactive)
08:25AM	Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) (InvestorsHub)
Jun-25-26 04:01PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Jun-23-26 04:00AM	Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering (GlobeNewswire) +6.59%
Jun-22-26 07:00AM	Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 (GlobeNewswire)
Jun-10-26 07:00AM	Ligand Announces 2026 Investor Day in New York City (GlobeNewswire)
04:01PM	Loading…
May-27-26 04:01PM	Ligand to Participate in June Investor Conferences (GlobeNewswire)
May-07-26 07:28AM	Ligand: Q1 Earnings Snapshot (Associated Press) -9.55%
07:00AM	Ligand Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:01PM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-27-26 10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
09:10AM	Ligand Pharmaceuticals buying Xoma Royalty for $739 million (Quartz)
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Apr-22-26 07:00AM	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +8.85%
Mar-26-26 07:00AM	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team (GlobeNewswire)
Mar-12-26 04:25PM	How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma (Investor's Business Daily)
Mar-11-26 01:49PM	Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says (Proactive)
09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
06:11AM	Loading…
06:11AM	Ligand initiated with a Buy at BofA (TipRanks)
Mar-10-26 05:14PM	IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out (Investor's Business Daily)
Mar-06-26 12:47PM	This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% (Investor's Business Daily)
09:12AM	These Are The 5 Best Stocks To Buy Or Watch Now (Investor's Business Daily)
Mar-04-26 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 05:03PM	Ligand Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:10PM	Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highlights: Surpassing Expectations and ... (GuruFocus.com)
07:50AM	Ligand: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 04:10PM	Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J (Investor's Business Daily)
08:44AM	Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal (Investor's Business Daily)
Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

MBATodd Christopher Davis

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zimmermann Martine	Director	Sep 10 '26	Sale	285.00	1,200	342,000	3,897	Sep 14 04:59 PM
MARTINE ZIMMERMANN	Director	Sep 10 '26	Proposed Sale	285.00	1,200	342,000		Sep 10 04:01 PM
Reardon Andrew	CLO & Secretary	Sep 03 '26	Sale	286.09	5,000	1,430,434	36,514	Sep 08 06:34 PM
ANDREW REARDON	Officer	Sep 03 '26	Proposed Sale	286.92	15,000	4,303,800		Sep 03 04:40 PM
Espinoza Octavio	Chief Financial Officer	Aug 12 '26	Option Exercise	56.91	31,641	1,800,574	59,337	Aug 14 05:05 PM
Espinoza Octavio	Chief Financial Officer	Aug 12 '26	Sale	292.06	31,641	9,241,229	27,696	Aug 14 05:05 PM
Haas Jason	Director	Aug 12 '26	Option Exercise	51.56	6,138	316,475	11,119	Aug 14 05:04 PM
Haas Jason	Director	Aug 12 '26	Sale	292.81	7,138	2,090,062	3,981	Aug 14 05:04 PM
OCTAVIO ESPINOZA	Officer	Aug 12 '26	Proposed Sale	288.75	31,641	9,136,339		Aug 12 04:33 PM
Jason Haas	Director	Aug 12 '26	Proposed Sale	292.81	7,138	2,090,062		Aug 12 04:23 PM
Reardon Andrew	CLO & Secretary	Aug 03 '26	Option Exercise	52.27	5,000	261,350	46,514	Aug 04 06:42 PM
Reardon Andrew	CLO & Secretary	Aug 03 '26	Sale	288.99	5,000	1,444,951	41,514	Aug 04 06:42 PM
Reardon Andrew	CLO & Secretary	Jul 01 '26	Option Exercise	52.27	5,000	261,350	46,514	Jul 06 05:11 PM
Reardon Andrew	CLO & Secretary	Jul 01 '26	Sale	313.28	5,000	1,566,377	41,514	Jul 06 05:11 PM
ANDREW REARDON	Officer	Jul 01 '26	Proposed Sale	316.09	10,000	3,160,900		Jul 01 04:57 PM
Sabba Stephen L	Director	Jun 16 '26	Option Exercise	66.13	2,145	141,849	35,774	Jun 18 08:37 AM
Sabba Stephen L	Director	Jun 16 '26	Sale	254.00	2,145	544,830	33,629	Jun 18 08:37 AM
STEPHEN L. SABBA	Director	Jun 16 '26	Proposed Sale	254.00	2,145	544,830		Jun 16 04:30 PM
Haas Jason	Director	Jun 12 '26	Option Exercise	51.56	4,000	206,240	11,442	Jun 15 09:06 PM
Haas Jason	Director	Jun 12 '26	Sale	255.58	6,461	1,651,320	4,981	Jun 15 09:06 PM
Aryeh Jason	Director	Jun 11 '26	Sale	250.00	4,500	1,125,000	102,580	Jun 12 05:27 PM
Aryeh Jason	Director	Jun 10 '26	Sale	250.00	500	125,000	107,080	Jun 12 05:27 PM
LAMATTINA JOHN L	Director	Jun 10 '26	Sale	250.88	4,591	1,151,774	26,969	Jun 12 05:26 PM
JASON HAAS	Director	Jun 12 '26	Proposed Sale	256.00	6,461	1,654,016		Jun 12 04:09 PM
Aryeh Jason	Director	Jun 11 '26	Proposed Sale	249.97	4,500	1,124,880		Jun 11 12:21 PM
Aryeh Jason	Director	Jun 10 '26	Proposed Sale	249.96	500	124,980		Jun 10 04:45 PM
JOHN L LAMATTINA	Director	Jun 10 '26	Proposed Sale	250.88	4,519	1,133,711		Jun 10 04:07 PM
Aryeh Jason	Director	Jun 10 '26	Proposed Sale	249.35	5,000	1,246,750		Jun 10 01:41 PM
Reardon Andrew	CLO & Secretary	Jun 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Jun 02 06:22 PM
Reardon Andrew	CLO & Secretary	Jun 01 '26	Sale	227.06	5,000	1,135,316	41,382	Jun 02 06:22 PM
Espinoza Octavio	Chief Financial Officer	May 27 '26	Option Exercise	57.58	1,736	99,966	27,679	May 28 07:43 PM
KOZARICH JOHN W	Director	May 13 '26	Option Exercise	69.51	1,575	109,478	43,361	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Option Exercise	69.51	459	31,905	42,245	May 14 09:08 PM
KOZARICH JOHN W	Director	May 13 '26	Sale	223.50	1,575	352,012	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 01 '26	Sale	231.80	467	108,251	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Sale	224.00	459	102,816	41,786	May 14 09:08 PM
JOHN KOZARICH	Director	May 13 '26	Proposed Sale	223.50	1,575	352,012		May 13 04:09 PM
JOHN KOZARICH	Director	May 12 '26	Proposed Sale	224.00	459	102,816		May 12 05:45 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Option Exercise	52.27	5,000	261,350	46,382	May 04 08:20 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Sale	231.31	5,000	1,156,556	41,382	May 04 08:20 PM
KOZARICH JOHN W	Director	May 01 '26	Proposed Sale	229.87	467	107,349		May 01 04:16 PM
KOZARICH JOHN W	Director	Apr 01 '26	Sale	202.23	467	94,440	42,253	Apr 02 07:43 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Apr 02 06:56 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Sale	201.24	5,000	1,006,224	41,382	Apr 02 06:56 PM
KOZARICH JOHN W	Director	Apr 01 '26	Proposed Sale	203.50	467	95,034		Apr 01 04:10 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Option Exercise	114.15	2,161	246,678	32,885	Mar 31 05:53 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Sale	200.76	2,161	433,842	30,724	Mar 31 05:53 PM
Sabba Stephen L	Director	Mar 23 '26	Sale	207.87	1,000	207,873	32,793	Mar 25 11:13 AM
STEPHEN L. SABBA	Director	Mar 23 '26	Proposed Sale	207.87	1,000	207,873		Mar 23 04:04 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Option Exercise	92.65	2,405	222,823	24,067	Mar 13 07:29 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Sale	225.00	3,057	687,825	21,010	Mar 13 07:29 PM
OCTAVIO ESPINOZA	Officer	Mar 11 '26	Proposed Sale	212.29	3,057	648,971		Mar 11 04:42 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Option Exercise	52.27	5,000	261,350	41,869	Mar 06 06:51 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Sale	206.35	5,000	1,031,770	36,869	Mar 06 06:51 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Option Exercise	63.49	2,073	131,609	35,085	Mar 06 06:49 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Sale	205.83	13,423	2,762,822	21,662	Mar 06 06:49 PM
JOHN L LAMATTINA	Director	Mar 06 '26	Proposed Sale	200.76	2,161	433,842		Mar 06 04:17 PM
Sabba Stephen L	Director	Mar 03 '26	Option Exercise	69.51	2,034	141,383	35,827	Mar 05 11:05 AM
Sabba Stephen L	Director	Mar 03 '26	Sale	201.50	2,034	409,851	33,793	Mar 05 11:05 AM
KOZARICH JOHN W	Director	Mar 02 '26	Sale	200.50	467	93,632	42,720	Mar 04 09:04 PM
ANDREW REARDON	Officer	Mar 04 '26	Proposed Sale	204.24	20,000	4,084,800		Mar 04 04:44 PM
OCTAVIO ESPINOZA	Officer	Mar 04 '26	Proposed Sale	204.24	13,423	2,741,514		Mar 04 04:39 PM
STEPHEN L. SABBA	Director	Mar 03 '26	Proposed Sale	201.50	2,034	409,851		Mar 03 04:27 PM
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGND

Ligand Pharmaceuticals Inc

Upgrade your Finviz experience